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Glucagon-like peptide-1 analogue, 
liraglutide, in experimental cerebral malaria: 
implications for the role of oxidative stress 
in cerebral malaria
Brian DellaValle1,2,3*, Casper Hempel1,3, Trine Staalsoe1,3, Flemming Fryd Johansen2 
and Jørgen Anders Lindholm Kurtzhals1,3
Abstract 
Background: Cerebral malaria from Plasmodium falciparum infection is major cause of death in the tropics. The 
pathogenesis of the disease is complex and the contribution of reactive oxygen and nitrogen species (ROS/RNS) in 
the brain is incompletely understood. Insulinotropic glucagon-like peptide-1 (GLP-1) mimetics have potent neuro-
protective effects in animal models of neuropathology associated with ROS/RNS dysfunction. This study investigates 
the effect of the GLP-1 analogue, liraglutide against the clinical outcome of experimental cerebral malaria (ECM) and 
Plasmodium falciparum growth. Furthermore the role of oxidative stress on ECM pathogenesis is evaluated.
Methods: ECM was induced in Plasmodium berghei ANKA-infected C57Bl/6j mice. Infected Balb/c (non-cerebral 
malaria) and uninfected C57Bl/6j mice were included as controls. Mice were treated twice-daily with vehicle or lira-
glutide (200 μg/kg). ROS/RNS were quantified with in vivo imaging and further analyzed ex vivo. Brains were assayed 
for cAMP, activation of cAMP response element binding protein (CREB) and nitrate/nitrite. Plasmodium falciparum was 
cultivated in vitro with increasing doses of liraglutide and growth and metabolism were quantified.
Results: The development and progression of ECM was not affected by liraglutide. Indeed, although ROS/RNS were 
increased in peripheral organs, ROS/RNS generation was not present in the brain. Interestingly, CREB was activated in 
the ECM brain and may protect against ROS/RNS stress. Parasite growth was not adversely affected by liraglutide in 
mice or in P. falciparum cultures indicating safety should not be a concern in type-II diabetics in endemic regions.
Conclusions: Despite the breadth of models where GLP-1 is neuroprotective, ECM was not affected by liraglutide 
providing important insight into the pathogenesis of ECM. Furthermore, ECM does not induce excess ROS/RNS in the 
brain potentially associated with activation of the CREB system.
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Background
The Plasmodium parasite is estimated to infect hundreds 
of millions worldwide carrying an annual death toll of 
approximately 0.5 million [1]. Cerebral malaria (CM) 
constitutes a large portion of the mortality burden. The 
pathogenesis of CM is complex involving a vascular com-
ponent with parasite-induced venule blockage, platelet 
activation, blood–brain barrier (BBB) disruption and 
an inflammatory component with activation of astro-
cytes, microglia, complement system, and lymphocytes. 
Ultimately; the consequences of this dysfunction can be 
seizures, coma and death [2–4]. Oxidative stress is pre-
sent throughout the body from the endogenous immune 
response and the presence of reactive free haem from 
lysis of infected erythrocytes (iRBC) [5–7]. Interestingly, 
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although oxidative stress is present systemically, it has 
been suggested that neither cerebral mitochondrial per-
formance [8, 9] nor antioxidant buffering [10–13] seems 
decisively compromised in fatal murine and human CM.
Glucagon-like peptide-1 (GLP-1), recently emerging 
as a front-line treatment for type II diabetes mellitus 
(DM), has been shown to have potent neuroprotective 
properties. GLP-1 receptor agonist treatment improves 
outcomes in experimental models of stroke, Parkin-
son’s disease and Alzheimer’s disease [14–16]. Moreo-
ver, the GLP-1 analogue, liraglutide, is neuroprotective 
against murine traumatic brain injury (TBI) and this 
effect is closely associated with the cytoprotective cAMP 
response element binding protein (CREB) pathway [17]. 
In addition to the potential cytoprotective effects of 
CREB-driven protective proteins, GLP-1 has also been 
suggested to promote endothelial cell nitric oxide pro-
duction, up-regulate haem oxygenase-1 [18, 19], and 
reduce neuroinflammation in vivo [20–23], all previously 
reported to protect against experimental CM (ECM) [7, 
20, 24]. The broad spectrum of neuroprotective effects 
reported after GLP-1 receptor agonist treatment and its 
safety profile in humans led us to investigate its poten-
tial as a therapeutic treatment against murine CM. In 
this investigation, this therapeutic potential is assessed 
with the GLP-1 receptor agonist, liraglutide: a long-act-
ing GLP-1 analogue designed to extend the half-life of 
GLP-1 receptor activation [25] that can cross the BBB 
[26].
Finally, the prevalence of obesity and type II DM is ris-
ing in malaria endemic regions of low and middle-income 
countries [27] and therefore the safety of liraglutide treat-
ment on parasite growth and metabolism was evaluated.
Methods
Liraglutide treatment of Plasmodium berghei‑induced 
cerebral malaria
All animal experiments were approved by the Dan-
ish Animal Experiments Inspectorate according to the 
license 2012-15-2934-00449. Survival study experiments 
were designed from a power analysis that suggested 14 
mice per group would be powered to 80 % at 95 % con-
fidence for detecting a 50 % reduction in mortality. Ani-
mals were kept under standard conditions with food/
water access ad libitum, and all studies were conducted to 
minimize suffering and in accordance with a pre-defined 
humane endpoint of body temperature <32 °C [28].
Stock Plasmodium berghei strain ANKA parasites 
characterized previously for disease progression were 
thawed and injected into a pilot mouse. After 4 days of 
in vivo growth, 104 iRBCs were injected intra peritoneal 
(i.p.) into female C57Bl/6j mice for modeling ECM or 
female Balb/c mice for modeling non-cerebral malaria 
(NCM) [(Taconic, Denmark), age 6–8 weeks]. To evalu-
ate the potential neuroprotective effects of liraglutide in 
ECM, liraglutide was administered at 200  μg/kg twice-
daily. Initial pilot experiments in ECM were performed 
with 50, 200, 400  μg/kg and obtained similar results. 
In previous work, three increasing doses of liraglutide 
(100, 200, and 400 μg/kg) were investigated as a protec-
tive agent in a model of murine TBI [17] where 200 μg/
kg was the most effective against brain damage. Moreo-
ver, this dose is matched to the dosing in the clinic for 
anti-diabetic effect in mice [29]. Thus, high-powered 
experiments were performed at a dose of 200  μg/kg. 
Maintaining a translational focus in the study, liraglutide 
was administered from day 4 post-infection to mimic a 
critical care scenario: day 4 coincides with detection of 
parasitaemia, and the beginning of damage to the olfac-
tory bulb [30].
Thus, on day 4 post-infection mice were randomly 
assigned to different treatment arms: twice-daily vehicle 
s.c. (PBS; n = 15), twice-daily liraglutide s.c. (Novo Nor-
disk, DK; n  =  15), or once-daily 5000  IU recombinant 
human Erythropoietin i.p. (Epo, Eprex®, Janssen-Cilag, 
Switzerland; n  =  8). Epo treatment from day 4 com-
pletely protects from ECM development [8, 31] and was 
therefore included as a positive control group. This ECM 
study was repeated to confirm results with smaller sam-
ple sizes [n = 7 (vehicle), 8 (liraglutide)]. NCM mice were 
included into evaluate the interaction between liraglutide 
and parasite growth and to control for the cerebral com-
ponent of the P. berghei infection. These two treatment 
arms (vehicle and liraglutide) were included in an experi-
ment with ECM and NCM mice (n =  10 for all groups 
and treatments).
Mice were monitored twice daily on day 4 and three 
times daily from day 5. 2 μL of blood from the tail vein 
were sampled from day 5 for parasitaemia enumeration. 
Parasites were enumerated with flow cytometry using 
acridine orange labeling and FACScanto flow cytometer 
(BD Biosciences, CA, US) as previously described [32].
ECM progression was monitored based on presenta-
tion of ruffled fur, ataxia, hemiplegia, seizures, coma and 
core body temperature reduction [28, 33]. This study 
was conducted with a pre-defined humane endpoint: 
animals were deemed ‘terminal’ when they registered a 
body temperature below 32  °C. Body temperature was 
measured three-times daily, non-invasively with an infra-
red thermometer (Testo 845, Testo, Germany) and fur-
ther confirmed with rectal probe (DM852, Ellab, DK) if 
the measurement was below 32  °C as described in [34]. 
Mice were killed by cervical dislocation and brain was 
observed after removal of skull for presence of haemor-
rhage to further verify the diagnosis of ECM. Finally, 
a group of healthy C57Bl/6j mice were included and 
Page 3 of 11DellaValle et al. Malar J  (2016) 15:427 
treated from day 4 until day 8 with vehicle or liraglutide 
(n = 8, 8).
Reactive oxygen/nitrogen species visualization
In order to visualize ROS/RNS species generation in CM 
infection in real-time, the highly sensitive luminol deriva-
tive, L-012 was used [35]. Plasmodium berghei-infected 
mice were injected with 75 mg/kg L-012 i.p. from day 5 
post infection. Mice were anesthetized with isoflurane 
and chemiluminescence was imaged (dorsal orienta-
tion) with a CCD camera 15  min after injection with a 
60 s exposure. Thereafter a supine acquisition was taken 
(60 s exposure). In vivo images were acquired once daily 
thereafter. Animals that were deemed terminally ill were 
injected with the luminescent probe and cervically dislo-
cated 15 min post-injection. Organs were rapidly exposed 
for light emission and an ex  vivo image was acquired 
(60 s). Epo prevented ECM in all mice and thus were ter-
minated at the end of the experiment (day 9) along with 
uninfected mice for imaging of the organs. In a repeat 
experiment, P. berghei-infected mice were adminis-
tered vehicle from day 4 and ex vivo tissue images were 
acquired in mice deemed terminal. Images were quanti-
fied with Living Image software (Perkin-Elmer, USA). All 
quantifications are reported as the difference between 
regions of interest and background signal.
Cerebral CREB, cAMP, and nitrate/nitrite levels
Brains were removed, split into olfactory bulb, cerebel-
lum, and two cerebral hemispheres, snap frozen in liquid 
nitrogen and maintained at −80 °C. One hemisphere was 
designated for immunoblotting and nitrate/nitrite assay 
and was homogenized in PhosphoSafe extraction reagent 
(catalogue number 71296, Millipore, DK) with protease 
inhibitor cocktail (mini complete, Roche, DK), protein 
content quantified (BioRad DC protein assay kit, DK), 
and stored at −22 °C.
One hemisphere was processed and assayed for cAMP 
determination as per manufacturers recommendations 
(Enzo Life Sciences, DK) in hydrochloric acid.
Immunoblotting was optimized and performed with 
standard western blot principles. All homogenates were 
thawed and mixed in sample buffer (100 mM DTT, Lae-
mmli buffer) and heated at 95  °C for 5  min. Based on 
optimization experiments, 25 µg protein per animal from 
one cerebral hemisphere was loaded into pre-cast poly-
acrylamide gels (12 % bis–tris; NuPAGE, Life Technolo-
gies, DK) and gels run in MES buffer at 150 V for 60 min. 
Gels were transferred to PVDF membranes (BioRad) at 
30 V for 60 min. Membranes were then washed in TBS 
and placed in blocking solution (5 % skim milk powder—
(CREB) or bovine serum albumin- (phospho-CREB) 
TBS-Tween20 (TBST) for 1  h at room temperature. 
Primary antibodies were applied CREB (1:1000, Cell 
Signaling, 9197), pCREB (Serine 133) (1:1000, Millipore, 
06-519), and GAPDH (1:10 000 Millipore, MAB 374) in 
appropriate blocking solution overnight at 4  °C. Mem-
branes were washed three times in TBST and secondary 
antibodies were applied in appropriate blocking solution: 
HRP-conjugated anti-rabbit/anti-mouse (DAKO, DK) at 
1:2000 and 1:3000 respectively for 1 h at room tempera-
ture. Membranes were washed three times in TBST and 
once in TBS. Membranes were incubated in SuperSignal 
Femto substrate (34095, Fisher, DK) and exposed with 
CCD camera (Bio-Rad Chemidoc XRS imager). Images 
were quantified with ImageJ software [36]. All protein 
signals are reported relative to the housekeeping protein, 
GAPDH.
Nitrate/nitrite assay was performed as per manufac-
turer’s recommendations (Cayman Chemical, DK) and 
normalized to protein content.
Plasmodium falciparum growth and metabolism
Stock P. falciparum parasites of CSA-selected Palo Alto 
(PA) strain were chosen to investigate the effects of lira-
glutide on parasite growth based on previous growth cri-
teria as described in detail in [37]. Parasites maintained 
at the Centre for Medical Parasitology were thawed and 
cultured at 37  °C in Albumax-enriched, HEPES buff-
ered RPMI culture media: RPMI (Gibco, DK), albumax 
(Gibco), hypoxanthine (Sigma-Aldrich, DK), and gen-
tamicin (Gibco) [37]. Stock cultures were diluted to 0.5 % 
and cultured in sterile 96-well microplates in vehicle 
(PBS) or increasing doses of liraglutide (0.1–100 μg/mL). 
Artesunate (10  ng/mL, Sigma-Aldrich) was included 
as a positive control for growth inhibition. Media and 
treatments were removed and replenished after 24  h 
and parasitaemia quantified by flow cytometry [32]. In 
a repeat experiment, P. falciparum parasites were cul-
tured in sterile 24-well plates with the same treatment 
groups. Media and drugs were exchanged and replen-
ished after 24 h. After 48 h, media was removed, spun at 
4 °C and the supernatant frozen at −80 °C for metabolite 
quantification.
Metabolite assay
Media from 24-well cultures were thawed and fed into a 
blood-gas and metabolite analyzer (ABL 725 Analyzer, 
Radiometer, DK) as described previously [37]. Media 
were assayed for concentration of glucose, lactate, H+ 
(pH), Na+, K+, and Ca2+.
Data analysis
Data sets were tested for normality (Shapiro–Wilk) and 
equal variance (Barlett’s) before statistical analyses were 
performed. Non-normal data sets were log-transformed, 
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and tested for normality. All data sets were either normal 
or normalized after log-transformation and thereafter 
analysis was performed with parametric tests. Survival 
data were analysed with log-rank test of Kaplan–Meier 
curves. One-way ANOVA with Holm-Sidak correction 
was performed on ex  vivo L-012 chemiluminescence 
data, immunoblotting, cAMP and nitrate/nitrite assays, 
and cultured-parasite growth and metabolism data. 
Two-way ANOVA repeated measures was performed on 
in vivo parasitaemia data and in vivo L-012 chemilumi-
nescence data. Normal data is presented as mean + SEM. 
and log transformed data as geometric mean  +  95  % 
confidence intervals unless otherwise stated. Significant 
differences are reported with p values below 0.05. Sta-
tistical analyses were performed with Graphpad Prism 6 
software.
Results
Liraglutide treatment in development and progression 
of ECM and NCM
Based on the neuroprotective effects of liraglutide in 
murine TBI [17], the effects of twice-daily liraglutide at 
200  μg/kg were investigated. The vast majority of vehi-
cle—(31 of 32) and liraglutide (31 of 33)—treated mice 
developed moribund clinical presentation, major body 
temperature reduction (<32  °C) and macroscopic cer-
ebral haemorrhage. Epo treatment protected all mice 
from clinical signs of ECM, and macroscopic cerebral 
haemorrhage. Liraglutide treatment did not affect ECM 
progression (Fig.  1). Moreover, parasite growth in ECM 
animals and NCM was not affected by liraglutide treat-
ment (Fig.  1b). In the first experiment with liraglutide 
treatment, parasitaemia was slightly higher in liraglutide-
treated animals. This was not the case in the subsequent 
two experiments.
In vivo imaging in ECM: reactive oxygen/nitrogen species 
generation is high in ECM mice, but is absent in the 
terminal ECM brain
Mice from all three infected groups were followed with 
in  vivo imaging for ROS/RNS generation from day 5 
post-infection. Chemiluminescent signals were detected 
in the lower abdomen from day 5. Interestingly, no signal 
was detected in the brains of any mice above background 
signal throughout the development of ECM despite neu-
rological symptoms and cerebral haemorrhage (Fig.  2a). 
From day 5, L-012 signal from abdomen of vehicle-
treated mice tended to increase until day 8 where mice 
deemed-terminal (i.e. body temperature <32  °C) had 
significantly reduced abdominal signal (p  <  0.05–0.001) 
(Fig.  2b, c). A similar phenomenon was observed in 
liraglutide mice in the terminal phase (p  <  0.001). Epo-
treated mice emitted a similar abdominal signal as 
vehicle and liraglutide-treated mice from day 5 but did 
not experience the marked reduction in abdominal signal 
at day 8 seen in the other groups (change in median from 
day 7: 81  % (vehicle), 93  % (liraglutide) reduction; Epo: 
no change (p = 0.9). In the thoracic region, there was no 
significant fluctuation over time and the signal was not 
affected by treatments (Fig. 2b, d).
Ex vivo quantification of ROS/RNS in brain, lungs, spleen, 
adipose and intestine of mice with fulminant ECM
Tissues were dissected from terminal mice (i.e. body tem-
perature <32  °C) and imaged for chemiluminescence. 
No signal above background threshold was detected in 
Fig. 1 Effects of liraglutide and erythropoietin on parasite growth 
and animal survival after Plasmodium berghei ANKA infection. Plasmo-
dium berghei ANKA infected C57Bl/6j [experimental cerebral malaria 
(ECM; closed line)] or Balb/c [non-cerebral malaria (NCM; dotted line)] 
mice were administered vehicle (black) or liraglutide (Lira: 200 μg/
kg; blue) from day 4 post infection. Finally, a group of ECM mice was 
administered erythropoietin (red, Epo) from day 4 post infection. a 
Survival in ECM mice refers to a pre-determined humane endpoint 
where the animal is deemed terminal when the body temperature is 
<32 °C. Survival data is presented as a Kaplan–Meier plot. Parasi-
taemia was enumerated by flow cytometry as described in detail 
in [32]. Reticulocytes were separated from infected erythrocytes by 
gating reticulocytes from uninfected control animals. Parasitaemia 
is presented as line graphs + SEM. All data in a and ECM animals in 
b are the combined data from three separate experiments (n = 32, 
33). NCM (n = 10, 10) and Epo (n = 8) mice are the results from one 
experiment
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Fig. 2 In vivo and ex vivo visualization and quantification of ROS/RNS in Plasmodium berghei-infected mice treated with liraglutide and erythropoi-
etin. Reactive oxygen and nitrogen species (ROS/RNS) were visualized and quantified in experimental cerebral malaria. Animals were administered 
vehicle (white), liraglutide (Lira; black), or Epo (red) from day 4 of P. berghei infection. ROS/RNS probe, L-012, was administered at 75 mg/mL i.p. 
from day 5 post infection and mice were imaged 15 min post injection for chemiluminescence under isoflurane anesthesia. Animals were imaged 
[dorsal (a) and supine (b)] daily (photos provided are from day 7). In vivo images were quantified in regions of interest [abdomen (c), thorax (d)] and 
presented as difference from background. Animals presented in b are representative of day 7 in each treatment group. Animals deemed terminal 
through humane endpoints described above (i.e. body temperature <32 °C) were injected with L-012. 15 min post-injection, organs were removed, 
imaged ex vivo for chemiluminescence and reported background-corrected. e Brains emitted no signal above background in all terminal mice 
regardless of treatment (n = 27) nor in Epo treated mice. f Lung, spleen, adipose, intestine chemiluminescence from infected animals (vehicle n = 19, 
19, 18, 19; Lira n = 8, 7, 4, 8; Epo n = 5, 7, 5, 7) and uninfected controls (gray, n = 4). Data was analyzed after log-transformation and presented as bar 
graphs of median + interquartile range on a log10 y-axis. Significant differences are reported when p values were <*0.05, **0.01, ***0.001
Page 6 of 11DellaValle et al. Malar J  (2016) 15:427 
whole brains or when sliced in a brain matrix in any mice 
(Fig. 2e). ROS/RNS generation was detected in the lungs, 
spleen, adipose tissue and intestine of terminal ECM 
(Fig. 2f ) and Epo-treated mice. Uninfected mice did not 
emit chemiluminescence in the adipose, lungs or brain 
tissue but developed a signal in the intestinal tract and 
spleen in 2 of 5 mice (Fig. 2f ). Liraglutide treatment did 
not significantly affect the ROS/RNS generation in lungs, 
spleen, adipose, or intestine. Curative Epo treatment 
significantly reduced ROS/RNS in the lungs (p < 0.001), 
spleen (p < 0.01) and adipose tissue (p < 0.001) compared 
to vehicle. Intestinal ROS/RNS generation was similar for 
all groups (p = 0.36). These measurements were repeated 
in vehicle-treated mice injected from day 4 (n = 7) in a 
subsequent study. Indeed, no signal was detected in the 
brain of terminal mice despite severe neurological symp-
toms and cerebral haemorrhage. Chemiluminescence 
was detected in lungs, spleen, adipose and intestinal 
tissue.
Activation of CREB in ECM and the effects of liraglutide 
on CREB, cAMP and nitric oxide derivatives
In a previous investigation in TBI, liraglutide treatment 
markedly increased CREB activation and was protec-
tive against ROS/RNS accumulation and mitochondrial 
dysfunction [17]. As shown in Fig.  3a, CREB activation 
increased twofold (p < 0.001) with ECM when compared 
to healthy (p < 0.001) and NCM (p < 0.05) control mice. 
Nevertheless, liraglutide treatment did not increase acti-
vation of CREB in healthy, ECM, or NCM mice when 
compared to vehicle. Interestingly, liraglutide treatment 
did increase cAMP levels in the brains of healthy mice 
(twofold, p < 0.05) but did not increase cAMP in diseased 
ECM or NCM mice (Fig.  3b). Nitrate and nitrite levels 
were assessed in the brain to evaluate markers down-
stream of nitric oxide production. There was no variation 
across the different groups of mice or between treatment 
arms in levels of cerebral nitrate or nitrite (Fig. 3c).
Effect of liraglutide on in vitro growth of Plasmodium 
falciparum
The results from the initial experiment concerning an 
effect of liraglutide treatment on parasite growth sug-
gested an investigation into the effect of liraglutide on 
the human malaria parasite, P. falciparum, although there 
was no effect of liraglutide in subsequent experiments. 
Plasmodium falciparum grew efficiently in 96-well 
plates in vitro in the presence of vehicle (PBS) after 48 h 
(~6.0 % parasitaemia; Fig. 4a; n = 5 distinct cultures) and 
artesunate inhibited parasite growth (n = 3). Incubation 
of P. falciparum with liraglutide 0.1–10  μg/mL did not 
affect parasite growth after 48  h (n  =  10 cultures/dos-
age; p  >  0.6). Liraglutide 100  μg/mL reduced in  vitro P. 
falciparum growth by 10 % (n = 10, p < 0.05). In a sec-
ond repeat experiment in 24-well plates, vehicle-treated 
cultures grew to 5.9 % parasitaemia (48 h growth, Fig. 4b, 
n =  6 cultures) and liraglutide doses 0.1–10  μg/mL did 
not affect parasite growth (n =  3–4, p =  0.7–0.9) after 
48  h. Liraglutide 100  μg/mL significantly reduced par-
asite growth by 16  % (n =  4, p  <  0.01). Analysis of the 
media after 48 h growth showed that iRBCs in all groups 
consumed glucose and produced lactate to the same lev-
els (Fig.  4c, d). Furthermore, levels of H+, K+, and Na+ 
in growth medium were similar in all groups (Fig. 4e–g). 
Interestingly, [Ca2+] was significantly reduced in the 
media from cultures with liraglutide treatment at 100 μg/
mL (p < 0.05) (Fig. 4h).
Discussion
Despite the premise for a therapeutic effect of GLP-1 
receptor agonism against ECM cerebrovascular pathol-
ogy these results indicate that liraglutide does not protect 
against ECM. After pilot testing of various doses and rig-
ourous experimentation with three high-powered stud-
ies (Fig. 1a), these data suggest that the finding presented 
here is robust for this analogue. With the scope of neuro-
pathological conditions that GLP-1 treatment improves 
[14–17], this finding is insightful for understanding both 
the pathogenesis of ECM and the neuroprotective mech-
anism of GLP-1 receptor agonism.
Plasmodium berghei ANKA infection initiates an oxi-
dative stress component from rupturing of RBCs releas-
ing free haem, hemozoin and immunogens and activated 
phagocyte respiratory bursting. Moreover, leukocytes 
isolated from murine and clinical CM generate higher 
ROS levels than those from healthy and non-CM controls 
[5, 6]. ROS/RNS were visualized in vivo using a sensitive 
probe, L-012, a luminol derivative with a higher sensitiv-
ity and signal to noise ratio than commonly used luminol 
and lucigenin [38, 39].
As suspected, these data show that mice with P. berghei 
infection are burdened with an increased ROS/RNS 
load throughout the body (Fig. 2). However, no emission 
signal was detected from the damaged brains, despite 
strong signals from damaged peripheral tissues (lungs, 
spleen, adipose). The absence of cerebral ROS/RNS signal 
through the development of fulminant, terminal ECM is 
intriguing. This finding is robust through two independ-
ent infections and a total of 27 mice in terminal-stage 
ECM (vehicle: n  =  19, liraglutide: n  =  8). Past experi-
ments with this imaging molecule have shown penetra-
tion in the brain [35], including work in TBI where the 
damaged brain shows high levels of ROS/RNS [17].
The role of ROS/RNS in the pathogenesis of ECM is 
indeed unclear [8, 9, 11, 12, 40, 41]. Antioxidant treat-
ments can be protective against ECM [41] and lipid 
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peroxidation increased and cerebral thiols decreased 
in late-stage ECM [40, 42, 43]. Moreover, neutrophils 
accumulate in the ECM brain over time [44]. Finally, 
micro-haemorrhage sites in the cerebellum show signs 
of possible stress in the vicinity of the haemorrhage 
[45]. Conversely, antioxidant therapy was unsuccessful 
in treatment of human CM and hydrogen sulfide donors 
were ineffective against ECM [10, 37]. Indeed, many 
antioxidant treatments can also have effects on immune 
function [12, 46], which may partly explain their effi-
cacy in ECM. Furthermore, although expression of 
some genes involved with oxidative stress is reduced in 
Fig. 3 Cerebral CREB, cAMP and nitrate/nitrite levels in Plasmodium berghei infection. Animals were administered vehicle (white) or liraglutide (Lira; 
gray) twice daily from day 4 post infection in C57Bl/6j mice for the experimental cerebral malaria (ECM) model and Balb/c mice for non-cerebral 
malaria (NCM) model. Healthy C57Bl/6j mice were treated with vehicle or liraglutide from day 4 to 8 of the experimental period. Brains were excised 
from terminal mice, the cerebrum isolated, split into two hemispheres, and flash frozen. One hemisphere was homogenized with phosphatase 
inhibition (Healthy: vehicle n = 7, Lira n = 6; ECM: vehicle n = 5, Lira n = 7; NCM: vehicle n = 6, Lira n = 6) and the other in a hydrochloric acid 
buffer for cAMP (Healthy: vehicle n = 7, Lira n = 7; ECM: vehicle n = 5, Lira n = 7; NCM: vehicle n = 7, Lira n = 7). Homogenates for immunoblotting 
were separated by SDS-PAGE and probed for CREB, pCREBser133 and normalized to GAPDH. Each antigen is normalized to GAPDH and presented as a 
pCREB/CREB ratio (a). Cerebral cAMP levels (b) and nitrate, nitrite levels (c, d; Healthy: vehicle n = 7, Lira n = 5; ECM: vehicle n = 4, Lira n = 5; NCM: 
vehicle n = 5, Lira n = 7) were assayed according to manufacturer’s recommendations. Data is presented as a bar graph with mean + SEM
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ECM [11], these seem to be compensated by increased 
anti-oxidant gene promotion [11, 47]: molecular mark-
ers of ROS damage (ROS-modified proteins) are largely 
unchanged [11, 12], mitochondrial function is pre-
served in ECM [8] and genetic removal of the primary 
endogenous reactive species generator NADPH oxidase 
does not improve ECM outcome [12]. Furthermore, 
poly(ADP-ribose) polymerase-1 knock-out mice are not 
protected from ECM, indicating that cytopathic hypoxia 
is not driving ECM [9]. These data are in support of 
these findings.
In a model of TBI, liraglutide reduced ROS/RNS and 
may have preserved mitochondrial function [17]. It is 
possible that an important component of the neuropro-
tective effect of GLP-1 involves the downstream buffering 
of cellular homeostasis and/or protection of mitochon-
drial function. These effects may be redundant in ECM 
and thus, be ineffective against fatality.
Fig. 4 Liraglutide has minor effects on Plasmodium falciparum growth and metabolism in vitro. Plasmodium falciparum parasites were cultured for 
48 h in the presence of increasing doses of liraglutide (Lira: 0.1–100 μg/mL) in a 96-well plates for parasitaemia measurements or b–h 24-well plates 
for metabolite measurements. Media including drug doses were exchanged after 24 h. Parasitaemia was enumerated with flow cytometry and 
metabolites were measured in ABL. Data is presented as dot plot with mean + SEM (96-well cultures (a): vehicle n = 5, Lira 0.1–100 ng/mL: n = 10, 
Artesunate n = 3; 24-well cultures (b); vehicle n = 6, Lira 0.1 ng/mL: n = 3, Lira 1–100 ng/mL: n = 4, Artesunate n = 2; Metabolism (c–h: Media: 
n = 3, uninfected erythrocytes (uRBCs): n = 4; vehicle: n = 4; Lira 0.1, 1 ng/mL: n = 2; Lira 10–100 ng/mL: n = 4)
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ROS/RNS were elevated in terminal mice in the lungs, 
spleen and adipose tissue- the preferred tissues where 
P. berghei parasites accumulated in previous studies [48, 
49]. Interestingly, L-012 photon emission decreased in 
terminal mice and may reflect vascular collapse often 
associated with ECM vasospasms and increased RBC/
iRBC/platelet/leukocyte aggregation in vessels through-
out the body [50]. Therapeutic Epo treatment reduced 
reactive species in the lungs, spleen and adipose tissue. It 
is unclear whether this is a direct effect or may be associ-
ated with the reduced parasite load in Epo treated mice, 
similar to previous reports [31].
The CREB pathway is a well-described transcriptional 
pathway associated with the production of a wide range 
of protective proteins in the brain [51]. This appears to 
be the first assessment of CREB dynamics in the brains 
of ECM and NCM mice. It is clear from Fig. 3a, that the 
cerebral CREB system is activated specifically in ECM 
but not in healthy or NCM mice. Since CREB is involved 
in up-regulation of proteins with anti-oxidant proper-
ties and preservation of the mitochondria (e.g. haem 
oxygenase-1, peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha, neuroglobin [52–54]), acti-
vation of this system in ECM may play a role in prevent-
ing ROS/RNS damage. Indeed, previous work by Linares 
et  al. [11] shows that haem oxygenase-1 is markedly 
increased in mice with ECM and considered an impor-
tant counterweight to potential oxidative damage. The 
activation of the CREB system observed here might be, in 
part, responsible for this mechanism.
In previous work, liraglutide treatment was protective 
after TBI and was associated with substantial pathology-
dependent CREB activation and increases in CREB-reg-
ulated protective proteins [17]. Interestingly, CREB was 
not activated by liraglutide in ECM. This may be related 
to absence of ROS/RNS stress in the brains of ECM mice 
whereas ROS/RNS were markedly increased in TBI. Fur-
thermore, it is intriguing that cAMP levels were increased 
in healthy mice by liraglutide but this did not translate to 
CREB activation. A similar phenomenon was observed 
previously, where liraglutide treatment did not activate 
CREB until pathology was introduced [17]. It seems that 
certain pathological events may be required for liraglu-
tide to induce the CREB pathway. This work in ECM 
suggests that marked oxidative stress may be important 
for a therapeutic effect of GLP-1 treatment in the brain. 
Differences in the therapeutic effect of GLP-1 may also 
be related to changes in GLP-1 receptor expression dur-
ing different pathological states. GLP-1 receptors are dis-
tributed in distinct brain regions in the healthy rodent 
brain [55]. Nevertheless, data is lacking on the receptor 
distribution under different pathological states. Finally, 
although GLP-1 treatment is known to increase the nitric 
oxide synthase enzyme, no increases in nitrous products 
downstream of nitric oxide production were detected in 
the brain. This may also contribute to the lack of effect of 
liraglutide in ECM, where nitric oxide is a known protec-
tive agent [20].
With an estimated 317 million people living with type 
II DM, a large portion of the burden resides in malaria 
endemic regions of the world [27]. It is therefore of 
interest to investigate the safety of type II DM treat-
ments for potential interactions between a drug and 
parasite growth and development of malaria. These data 
show that P. falciparum growth in  vitro and metabo-
lism (Fig. 4) is unaffected by increasing doses of liraglu-
tide (0.1–10 μg/mL). At a 100 μg/mL dosage, liraglutide 
treatment exerts inhibitory effects on parasite growth 
though is not likely to be achieved clinically due to gas-
trointestinal side effects associated with much lower 
doses [56, 57]. With three large in vivo experiments and 
in  vitro experiments involving the human pathogen, 
it does seem likely that liraglutide interacts adversely 
with P. falciparum in humans. This investigation there-
fore suggests that liraglutide is likely safe for adminis-
tration under co-morbidity circumstances with type II 
DM. Active post-marketing surveillance should still be 
applied.
Conclusions
This shows that liraglutide, a neuroprotective drug in 
a wide-range of experimental models, is not effective 
against ECM. This may be related to the lack of ROS/
RNS stress in the brain of ECM mice. Moreover, ROS/
RNS may be adequately regulated by activation of the 
CREB system during ECM. This study may, thus, provide 
important insight into the pathogenesis of ECM and the 
mechanism driving the neuroprotective effects of GLP-1.
Abbreviations
BBB: blood–brain barrier; CM: cerebral malaria; CREB: cyclic AMP response ele-
ment binding; DM: diabetes mellitus; ECM: experimental cerebral malaria; Epo: 
erythropoietin; GLP-1: glucagon-like peptide-1; iRBC: infected erythrocyte; 
NCM: non-cerebral malaria; PA: Palo Alto; pCREB: phosphorylatedSer133 cyclic 
AMP response element binding; ROS/RNS: reactive oxygen/nitrogen species; 
TBI: traumatic brain injury; TBST: tris-buffered saline-tween20.
Authors’ contributions
BD designed the study, conducted all the experiments, analyzed the data, 
and drafted the manuscript. CH designed the study and analyzed data. TS 
conducted the parasite growth experiments with BD. FFJ designed the study. 
JALK designed the study and analyzed data. All authors read and approved 
the final manuscript.
Author details
1 Department of Immunology and Microbiology, Centre for Medical Parasitol-
ogy, University of Copenhagen, Copenhagen, Denmark. 2 Department of Bio-
medical Sciences, Biotech Research and Innovation Center, Faculty of Health 
Sciences, University of Copenhagen, Copenhagen, Denmark. 3 Department 
of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, 
Denmark. 
Page 10 of 11DellaValle et al. Malar J  (2016) 15:427 
Acknowledgements
We wish to acknowledge the skill and technical abilities of the animal 
veterinarians at the University of Copenhagen and technical ability of Patrizia 
Hezel. We wish to express appreciation to Christophe Come (IVIS), and Bente 
Klarlund Pedersen (CCD camera) for use of machinery.
Competing interests
BD was partly funded by Novo Nordisk. Independence of the researchers was 
secured through an intellectual property rights agreement approved by the 
legal department of University of Copenhagen. Novo Nordisk has been allowed 
to read and comment the final manuscript although; in accordance with the 
IPR, the company had no influence on the experiments, content of the manu-
script or the decision to publish. The investigators have no competing interests 
and have no financial interests in the study drug, liraglutide. This does not alter 
the authors’ adherence to all policies on sharing data and materials.
Availability of data and materials
Data and materials are available upon request. Contact the corresponding 
author for details.
Consent for publication
All authors consent to the publication of this manuscript.
Ethics approval
All animal experiments were approved by the Danish Animal Experiments 
Inspectorate according to the license 2012-15-2934-00449.
Funding
We would like to thank the University of Copenhagen, Righospitalet, Novo 
Nordisk fund and Novo Nordisk for financial support.
Received: 29 April 2016   Accepted: 11 August 2016
References
 1. World Health Organization. World Malaria Report. Geneva: World Health 
Organization; 2015.
 2. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. 
Nat Rev Immunol. 2005;5:722–35.
 3. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE. A unified hypoth-
esis for the genesis of cerebral malaria: sequestration, inflammation and hemo-
stasis leading to microcirculatory dysfunction. Trends Parasitol. 2006;22:503–8.
 4. MacCormick IJ, Beare NA, Taylor TE, Barrera V, White VA, Hiscott P, et al. Cerebral 
malaria in children: using the retina to study the brain. Brain. 2014;137:2119–42.
 5. Brinkmann V, Kaufmann SH, Simon MM, Fischer H. Role of macrophages 
in malaria: O2 metabolite production and phagocytosis by splenic mac-
rophages during lethal Plasmodium berghei and self-limiting Plasmodium 
yoelii infection in mice. Infect Immun. 1984;44:743–6.
 6. Dubey ML, Rai SK, Ganguly NK, Kalra A, Varma SC, Mahajan RC. Genera-
tion of reactive oxygen species by blood monocytes in human Plasmo-
dium falciparum and P. vivax infections. APMIS. 1991;99:210–2.
 7. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S, et al. Heme 
oxygenase-1 and carbon monoxide suppress the pathogenesis of experi-
mental cerebral malaria. Nat Med. 2007;13:703–10.
 8. Karlsson M, Hempel C, Sjovall F, Hansson MJ, Kurtzhals JA, Elmer E. Brain 
mitochondrial function in a murine model of cerebral malaria and the 
therapeutic effects of rhEPO. Int J Biochem Cell Biol. 2013;45:151–5.
 9. Hempel C, Combes V, Hunt NH, Kurtzhals JA, Grau GE. CNS hypoxia is 
more pronounced in murine cerebral than noncerebral malaria and is 
reversed by erythropoietin. Am J Pathol. 2011;179:1939–50.
 10. Charunwatthana P, Abul Faiz M, Ruangveerayut R, Maude RJ, Rahman 
MR, Roberts LJ, et al. N-acetylcysteine as adjunctive treatment in severe 
malaria: a randomized, double-blinded placebo-controlled clinical trial. 
Crit Care Med. 2009;37:516–22.
 11. Linares M, Marin-Garcia P, Martinez-Chacon G, Perez-Benavente S, Puyet 
A, Diez A, et al. Glutathione peroxidase contributes with heme oxyge-
nase-1 to redox balance in mouse brain during the course of cerebral 
malaria. Biochim Biophys Acta. 2013;1832:2009–18.
 12. Sanni LA, Fu S, Dean RT, Bloomfield G, Stocker R, Chaudhri G, et al. Are 
reactive oxygen species involved in the pathogenesis of murine cerebral 
malaria? J Infect Dis. 1999;179:217–22.
 13. Dondorp AM, Planche T, de Bel EE, Angus BJ, Chotivanich KT, Silamut K, 
et al. Nitric oxides in plasma, urine, and cerebrospinal fluid in patients 
with severe falciparum malaria. Am J Trop Med Hyg. 1998;59:497–502.
 14. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 
receptor stimulation preserves primary cortical and dopaminergic neu-
rons in cellular and rodent models of stroke and Parkinsonism. Proc Natl 
Acad Sci USA. 2009;106:1285–90.
 15. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 
receptor stimulation reduces amyloid-beta peptide accumulation and 
cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzhei-
mers Dis. 2010;19:1205–19.
 16. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug 
liraglutide prevents degenerative processes in a mouse model of Alzhei-
mer’s disease. J Neurosci. 2011;31:6587–94.
 17. DellaValle B, Hempel C, Johansen FF, Kurtzhals JA. GLP-1 improves neuro-
pathology after murine cold lesion brain trauma. Ann Clin Transl Neurol. 
2014;1:721–32.
 18. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 
receptor, prevents PC12 cells from oxidative damage via MAP kinase 
pathway. Neurochem Int. 2007;51:361–9.
 19. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje 
HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced 
endothelial cell senescence through the activation of protein kinase A. 
Arterioscler Thromb Vasc Biol. 2010;30:1407–14.
 20. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, Frangos JA, 
et al. Low nitric oxide bioavailability contributes to the genesis of experi-
mental cerebral malaria. Nat Med. 2006;12:1417–22.
 21. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, et al. A GLP-1 
receptor agonist liraglutide inhibits endothelial cell dysfunction and 
vascular adhesion molecule expression in an ApoE-/- mouse model. Diab 
Vasc Dis Res. 2011;8:117–24.
 22. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al. 
Glucagon-like peptide-1 receptor activation reduces ischaemic brain dam-
age following stroke in type 2 diabetic rats. Clin Sci (Lond). 2012;122:473–83.
 23. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. 
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuro-
protection in mice transient focal cerebral ischemia. J Cereb Blood Flow 
Metab. 2011;31:1696–705.
 24. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, et al. 
Immunopathogenesis of cerebral malaria. Int J Parasitol. 2006;36:569–82.
 25. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, 
et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic 
properties suitable for once daily administration. J Med Chem. 2000;43:1664–9.
 26. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and 
lixisenatide, cross the blood brain barrier and enhance neurogenesis. 
BMC Neurosci. 2012;13:33.
 27. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. 
National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health examina-
tion surveys and epidemiological studies with 370 country-years and 2.7 
million participants. Lancet. 2011;378:31–40.
 28. Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JA. Recombinant 
human erythropoietin increases survival and reduces neuronal apoptosis 
in a murine model of cerebral malaria. Malar J. 2008;7:3.
 29. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. 
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body 
weight and food intake in obese candy-fed rats, whereas a dipeptidyl 
peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56:8–15.
 30. Zhao H, Aoshi T, Kawai S, Mori Y, Konishi A, Ozkan M, et al. Olfactory plays 
a key role in spatiotemporal pathogenesis of cerebral malaria. Cell Host 
Microbe. 2014;15:551–63.
 31. Hempel C, Hyttel P, Staalso T, Nyengaard JR, Kurtzhals JA. Erythropoietin 
treatment alleviates ultrastructural myelin changes induced by murine 
cerebral malaria. Malar J. 2012;11:216.
 32. Hein-Kristensen L, Wiese L, Kurtzhals JA, Staalsoe T. In-depth validation 
of acridine orange staining for flow cytometric parasite and reticulocyte 
enumeration in an experimental model using Plasmodium berghei. Exp 
Parasitol. 2009;123:152–7.
Page 11 of 11DellaValle et al. Malar J  (2016) 15:427 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 33. Curfs JH, Schetters TP, Hermsen CC, Jerusalem CR, van Zon AA, Eling WM. 
Immunological aspects of cerebral lesions in murine malaria. Clin Exp 
Immunol. 1989;75:136–40.
 34. Dellavalle B, Kirchhoff J, Maretty L, Castberg FC, Kurtzhals JA. Implementa-
tion of minimally invasive and objective humane endpoints in the study 
of murine Plasmodium infections. Parasitology. 2014;141:1621–7.
 35. Kielland A, Blom T, Nandakumar KS, Holmdahl R, Blomhoff R, Carlsen H. 
In vivo imaging of reactive oxygen and nitrogen species in inflammation 
using the luminescent probe L-012. Free Radic Biol Med. 2009;47:760–6.
 36. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of 
image analysis. Nat Methods. 2012;9:671–5.
 37. DellaValle B, Staalsoe T, Kurtzhals JA, Hempel C. Investigation of hydrogen 
sulfide gas as a treatment against P. falciparum, murine cerebral malaria, 
and the importance of thiolation state in the development of cerebral 
malaria. PLoS ONE. 2013;8:e59271.
 38. Nishinaka Y, Aramaki Y, Yoshida H, Masuya H, Sugawara T, Ichimori Y. 
A new sensitive chemiluminescence probe, L-012, for measuring the 
production of superoxide anion by cells. Biochem Biophys Res Commun. 
1993;193:554–9.
 39. Daiber A, Oelze M, August M, Wendt M, Sydow K, Wieboldt H, et al. Detec-
tion of superoxide and peroxynitrite in model systems and mitochondria 
by the luminol analogue L-012. Free Radic Res. 2004;38:259–69.
 40. Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, et al. 
Cognitive dysfunction is sustained after rescue therapy in experimental 
cerebral malaria, and is reduced by additive antioxidant therapy. PLoS 
Pathog. 2010;6:e1000963.
 41. Thumwood CM, Hunt NH, Cowden WB, Clark IA. Antioxidants can prevent 
cerebral malaria in Plasmodium berghei-infected mice. Br J Exp Pathol. 
1989;70:293–303.
 42. Reis PA, Estato V, da Silva TI, d’Avila JC, Siqueira LD, Assis EF, et al. Statins 
decrease neuroinflammation and prevent cognitive impairment after 
cerebral malaria. PLoS Pathog. 2012;8:e1003099.
 43. Ong PK, Melchior B, Martins YC, Hofer A, Orjuela-Sanchez P, Cabrales 
P, et al. Nitric oxide synthase dysfunction contributes to impaired cer-
ebroarteriolar reactivity in experimental cerebral malaria. PLoS Pathog. 
2013;9:e1003444.
 44. Porcherie A, Mathieu C, Peronet R, Schneider E, Claver J, Commere PH, 
et al. Critical role of the neutrophil-associated high-affinity receptor for 
IgE in the pathogenesis of experimental cerebral malaria. J Exp Med. 
2011;208:2225–36.
 45. Hackett MJ, Aitken JB, El-Assaad F, McQuillan JA, Carter EA, Ball HJ, et al. 
Mechanisms of murine cerebral malaria: multimodal imaging of altered 
cerebral metabolism and protein oxidation at hemorrhage sites. Sci Adv. 
2015;1:e1500911.
 46. Chaudhri G, Hunt NH, Clark IA, Ceredig R. Antioxidants inhibit prolif-
eration and cell surface expression of receptors for interleukin-2 and 
transferrin in T lymphocytes stimulated with phorbol myristate acetate 
and ionomycin. Cell Immunol. 1988;115:204–13.
 47. Imai T, Iwawaki T, Akai R, Suzue K, Hirai M, Taniguchi T, et al. Evaluating 
experimental cerebral malaria using oxidative stress indicator OKD48 
mice. Int J Parasitol. 2014;44:681–5.
 48. Fonager J, Pasini EM, Braks JA, Klop O, Ramesar J, Remarque EJ, et al. 
Reduced CD36-dependent tissue sequestration of Plasmodium-infected 
erythrocytes is detrimental to malaria parasite growth in vivo. J Exp Med. 
2012;209:93–107.
 49. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, Que 
I, et al. Murine malaria parasite sequestration: CD36 is the major receptor, 
but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci 
USA. 2005;102:11468–73.
 50. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ. Murine cerebral 
malaria is associated with a vasospasm-like microcirculatory dysfunction, 
and survival upon rescue treatment is markedly increased by nimodipine. 
Am J Pathol. 2010;176:1306–15.
 51. Lonze BE, Ginty DD. Function and regulation of CREB family transcription 
factors in the nervous system. Neuron. 2002;35:605–23.
 52. Liu N, Yu Z, Li Y, Yuan J, Zhang J, Xiang S, Wang X. Transcriptional regula-
tion of mouse neuroglobin gene by cyclic AMP responsive element 
binding protein (CREB) in N2a cells. Neurosci Lett. 2013;534:333–7.
 53. Lee B, Cao R, Choi YS, Cho HY, Rhee AD, Hah CK, et al. The CREB/CRE 
transcriptional pathway: protection against oxidative stress-mediated 
neuronal cell death. J Neurochem. 2009;108:1251–65.
 54. Handschin C. The biology of PGC-1alpha and its therapeutic potential. 
Trends Pharmacol Sci. 2009;30:322–9.
 55. Knudsen LB, Secher A, Hecksher-Sorensen J, Pyke C. Long-acting gluca-
gon-like peptide-1 receptor agonists have direct access to and effects on 
pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript 
neurons in the mouse hypothalamus. J Diabetes Investig. 2016;7(Suppl 
1):56–63.
 56. Deacon CF. Potential of liraglutide in the treatment of patients with type 
2 diabetes. Vasc Health Risk Manag. 2009;5:199–211.
 57. Sun F, Yu K, Yang Z, Wu S, Zhang Y, Shi L, et al. Impact of GLP-1 receptor 
agonists on major gastrointestinal disorders for type 2 diabetes mel-
litus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 
2012;2012:230624.
